YOLFTbeta
Neurogene Inc

Neurogene Inc

NGNE · NASDAQ · Healthcare / Biotechnology

23.93USD+0.03 (+0.13%)

Price History

Full chart

Market Stats

Previous Close23.90
Open23.96
Day Range23.29 – 24.50
52-Week Range15.93 – 43.66
Volume193.62K
Market Cap569.92M
P/E (TTM)0.00
Forward P/E0.00
EPS-5.07
Dividend Yield0.00%
Beta1.96
50-Day Avg35.51
200-Day Avg27.10

About

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Rachel L. McMinn Ph.D.
  • Employees131
  • Headquarters535 W 24th Street, New York, NY, United States, 10011, USA
  • Websitehttps://www.neurogene.com

Leadership

  • Dr. Rachel L. McMinn Ph.D.Founder, Executive Chair & CEO · b. 1973
  • Ms. Christine Mikail Cvijic J.D.President, CFO & Director · b. 1978
  • Dr. Julie Jordan M.D.Chief Medical Officer · b. 1972
  • Dr. Stuart Cobb Ph.D.Chief Scientific Officer · b. 1971
  • Ms. Lina LiExecutive Director of Investor Relations
  • Ms. Donna M. Cochener-Metcalfe J.D., L.L.M.Senior VP, General Counsel & Corporate Secretary · b. 1975
  • Dr. Andrew E. Mulberg CPI, FAAP, M.D.Senior VP of Regulatory Affairs, Quality Assurance & Quality Control
  • Mr. Ricardo JimenezSenior Vice President of Technical Operations
  • Mr. Arvind SreedharanSenior Vice President of Business Operations
  • Ms. Christina ShaferChief Commercial Officer · b. 1976

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-------25.00M--000925.00K0
Growth (%)---------------100.00%
Cost of Revenue125.60K130.78K59.57K135.95K----340.00K1.82M42.26M3.20M3.26M3.25M3.19M
Gross Profit-125.60K-130.78K-59.57K-135.95K---25.00M-340.00K-1.82M-42.26M-3.20M-3.26M-2.32M-3.19M
Gross Margin-------100.00%------251.03%-
Operating Expense10.30M7.55M9.32M22.24M---48.52M24.10M39.73M8.27M53.32M52.32M80.28M100.02M
Operating Income-10.43M-7.68M-9.38M-22.38M-21.34M-37.65M-51.12M-23.52M-24.44M-41.55M-50.53M-56.52M-55.58M-82.61M-103.21M
Operating Margin--------94.10%------8930.27%-
EBITDA-10.54M-7.54M-8.63M-21.65M-21.76M-37.00M-50.18M-31.58M-69.10M-31.46M-49.57M-51.99M-33.01M-71.89M-87.25M
EBITDA Margin--------126.32%------7771.35%-
Net Income-10.51M-7.71M-8.73M-23.82M-21.86M-37.00M-50.18M-31.59M-69.44M-33.28M-50.52M-55.19M-36.32M-75.14M-90.35M
Net Income Margin--------126.34%------8123.68%-
R&D8.58M5.91M7.54M17.94M15.80M28.38M36.27M32.79M6.32M24.34M42.26M47.51M44.39M60.92M75.01M
R&D as % of Total Revenue-------131.16%-----6585.62%-
Interest Expense--42.92K2.25M99.00K1.00K4.00K4.00K1.00K-02.00K12.00K12.00K5.00K
Interest Expense % of Total Revenue-------0.02%-----1.30%-

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.88M2.34M58.77M41.42M113.34M154.38M110.33M77.62M147.02M210.52M101.49M109.27M222.57M335.73M288.60M
Total Liabilities1.30M1.47M7.48M5.28M4.92M9.72M11.44M4.95M5.34M19.30M193.36M10.64M36.55M25.36M23.72M
Total Equity8.59M874.03K51.28M36.15M108.42M144.66M98.89M72.67M141.69M191.22M-91.88M98.63M186.02M310.38M264.89M
Cash9.24M2.00M54.13M14.91M39.53M32.30M52.03M76.93M143.09M192.56M70.54M82.02M148.21M136.59M103.84M
Total Debt--2.29M72.34K131.00K47.00K33.00K6.00K1.21M12.12M6.43M4.69M16.25M12.43M9.89M
Net Debt-9.24M-2.00M-51.84M-14.83M-39.40M-32.25M-52.00M-76.92M-141.88M-180.43M-64.11M-77.33M-131.96M-124.16M-93.95M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.80M-7.23M-7.94M-17.81M-20.27M-30.23M-44.72M-31.58M-15.39M-24.57M-46.40M-52.82M-51.42M-70.60M-77.17M
Investing Cash Flow-62.84K-6.45K-2.64M-23.57M-47.53M-48.06M64.01M55.95M-688.00K-2.22M-18.37M-2.23M25.64M-125.26M14.00M
Financing Cash Flow12.12M-19.58M45.28M92.95M71.11M423.00K570.00K82.24M77.14M51.06M66.53M92.48M184.07M30.43M
Capital Expenditure62.85K6.45K11.75K113.89K27.00K713.00K494.00K49.00K879.00K2.22M18.37M2.23M321.00K808.00K1.18M
Free Cash Flow-9.86M-7.24M-7.95M-17.92M-20.30M-30.94M-45.21M-31.63M-16.27M-26.79M-64.77M-55.05M-51.74M-71.41M-78.36M
FCF to OCF100.64%100.09%100.15%100.64%100.13%102.36%101.10%100.16%105.71%109.03%139.59%104.22%100.62%101.14%101.53%

Earnings

Report DateMay 13, 2014Aug 12, 2014Nov 10, 2014Mar 3, 2015May 12, 2015Aug 6, 2015Nov 10, 2015Mar 14, 2016May 10, 2016Aug 4, 2016Nov 9, 2016Mar 10, 2017May 9, 2017Aug 8, 2017Nov 8, 2017Mar 12, 2018May 8, 2018Aug 8, 2018Nov 7, 2018Mar 18, 2019May 6, 2019Aug 7, 2019Nov 13, 2019Mar 12, 2020May 6, 2020Aug 12, 2020Nov 9, 2020Mar 25, 2021May 12, 2021Aug 5, 2021Nov 4, 2021Mar 1, 2022May 9, 2022Aug 9, 2022Nov 14, 2022Mar 16, 2023May 10, 2023Aug 16, 2023Nov 14, 2023Mar 18, 2024May 10, 2024Aug 9, 2024Nov 18, 2024Mar 24, 2025May 8, 2025Aug 11, 2025Nov 13, 2025Mar 24, 2026May 13, 2026Aug 11, 2026Nov 12, 2026
EPS Estimate---0.45-0.76-0.81-0.56-0.45-0.37-0.35-0.41-0.58-0.51-0.51-0.51-0.59-0.57-0.66-0.59-0.21-0.79-0.23-0.05-0.04-0.28-0.23-0.21-0.22-0.24-0.23-0.26-0.28-0.30-0.30-0.30-0.30-0.19-0.22-0.04-0.03-1.17-0.95-1.03-1.22-1.13-1.12-1.16-1.09-1.24-1.27-1.40-1.39
EPS Actual-1.28-0.51-0.78-0.60-0.44-0.43-0.26-0.39-0.63-0.63-0.46-0.48-0.36-0.59-0.50-0.69-0.620.12-0.64-0.21-0.09-0.09-2.26-0.23-0.18-0.20-0.04-0.22-0.27-0.27-0.28-0.28-0.28-0.28-0.24-0.24-0.26-0.04-0.41-1.51-1.00-1.09-1.19-0.99-1.08-1.05-0.99-1.13-1.39-1.53-
Surprise---73.33%21.05%45.68%23.21%42.22%-5.41%-80.00%-53.66%20.69%5.88%29.41%-15.69%15.25%-21.05%6.06%120.34%-204.76%73.42%60.87%-80.00%-5550.00%17.86%21.74%4.76%81.82%9.95%-18.42%-3.05%-0.61%5.31%6.04%6.67%21.13%-26.32%-18.18%0.00%-1259.00%-29.06%-5.26%-5.83%2.46%12.39%3.57%9.48%9.17%8.87%-9.05%-9.29%-
Timing---------------------------------------After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursPre-market

Key Statistics & Ratios

Market Cap569.92M
Enterprise Value402.31M
Trailing P/E0.00
Forward P/E0.00
Price / Sales438.73
Price / Book2.85
EPS-5.07
Book Value13.72
Revenue (TTM)0
Gross Profit (TTM)-88.38M
EBITDA-117.99M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-45.31%
Return on Assets-27.98%
Shares Outstanding20.01M
Shares Float11.33M
Beta1.96
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 80.43
  • Strong Buy
    4
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
88.93%
Insiders
6.98%
Retail / Other
4.09%

Top Institutional Holders

  • Samsara BioCapital, LLC
    1.72M8.58%
  • Casdin Capital, LLC
    1.55M7.72%
  • Redmile Group, LLC
    1.41M7.06%
  • RTW INVESTMENTS, LLC
    1.36M6.81%
  • EcoR1 Capital, LLC
    1.27M6.35%
  • BlackRock Inc
    1.01M5.02%
  • Baker Bros Advisors LP
    991.69K4.96%
  • Balyasny Asset Management LLC
    718.39K3.59%
  • Trails Edge Capital Partners, LP
    714.88K3.57%
  • The Toronto-Dominion Bank
    681.34K3.40%
  • Jennison Associates LLC
    518.58K2.59%
  • Vanguard Capital Management, LLC
    514.73K2.57%
  • Citadel Advisors Llc
    408.98K2.04%
  • FMR Inc
    382.65K1.91%
  • Great Point Partners LLC
    352.18K1.76%
  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
    342.45K1.71%
  • State Street Corp
    313.00K1.56%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    520.96K2.60%
  • Franklin Biotechnology Discv A(acc)USD
    409.49K2.05%
  • iShares Russell 2000 ETF
    291.84K1.46%

Stock Splits

  • Dec 19, 20231:4
  • Sep 25, 20231:5